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Abstract 
Objective: We aimed to evaluate the efficacy and safety of the three dipeptidyl peptidase 4 (DPP‑4) inhibitors 
(vildagliptin, sitagliptin, and linagliptin) as add‑on therapy in Chinese patients with type 2 diabetes mellitus (T2DM)
inadequately controlled on dual combination of insulin and metformin or acarbose.
Methods: A total of 535 T2DM patients who failed to achieve glycemic control with insulin and a traditional oral 
hypoglycemic agent were randomized to receive vildagliptin, sitagliptin, or linagliptin. Body mass index, glycosylated 
hemoglobin (HbA1c), fasting and postprandial plasma glucose (FPG and PPG), insulin dose, and adverse events were 
evaluated during the study.
Results: The baseline HbA1c was 9.59 ± 1.84 % (vildagliptin group), 9.22 ± 1.60 % (sitagliptin group), and 
9.58 ± 1.80 % (linagliptin group). At week 12 it was 8.16 ± 1.29 % (vildagliptin), 8.56 ± 1.96 % (linagliptin), and 
8.26 ± 1.10 % (sitagliptin). The changes in HbA1c from baseline were −1.33 ± 0.11 % (vildagliptin), −0.84 ± 0.08 % 
(sitagliptin) and −0.81 ± 0.08 % (linagliptin), the vildagliptin group had the greatest reduction in HbA1c (P < 0.05). 
The proportions of patients that reached target HbA1c were 66.27 % (vildagliptin), 52.73 % (sitagliptin), and 55.49 % 
(linagliptin), the vildagliptin group had the highest one (P < 0.05). The baseline FPG and PPG values in the three 
groups were at the same level. At week 12, mean FPG levels in the vildagliptin (7.31 ± 1.50 mmol/L) and linagliptin 
(6.90 ± 1.55 mmol/L) groups were significantly lower than in the sitagliptin group (8.02 ± 4.48 mmol/L; P < 0.05); 
the linagliptin group had the lowest mean PPG followed by the vildagliptin group which was also significant lower 
(P = 0.000) than the sitagliptin group. Additionally, the required insulin dosage in the vildagliptin group was the low‑
est among the groups at weeks 6 and 12. Only mild AEs were reported during the study.
Conclusion: The three DPP‑4 inhibitors appear to be effective and safe as add‑on therapy for T2DM patients on dual 
combination of insulin and a traditional OHA. Vildagliptin was more effective in decreasing insulin requirement and 
achieving glycemic control when compared to the other two.
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Background
Type 2 diabetes mellitus (T2DM) affects over 300 million 
people worldwide [1]. The global prevalence of T2DM 
was estimated to be 9 % among adults aged over 18 years 
in 2014 [1]. Excluding accidents, diabetes is the fifth 
cause of death for women and the fourth for men in the 
USA [2]. In China, the total diabetes prevalence was 9.7 % 
(92.4 million adults) according to the China National 
Diabetes and Metabolic Disorders Study between 2007 
and 2008, while the prevalence of prediabetes was esti-
mated to be 15.5 % (148 million adults) [3]. The increas-
ing prevalence of diabetes has followed rapid economic 
growth, increases in life expectancy, and changes in life-
style [3]. Inadequate control of blood glucose in patients 
correlates with a higher risk for diabetes-related micro 
and macrovascular complications [4, 5]. The manage-
ment of diabetes aims at improving glycemic control to 
reduce the onset of complications [6]. Glycemic control 
is typically measured as reductions in glycosylated hemo-
globin (HbA1c).
T2DM is a progressive disease that often requires a 
combination of antidiabetic drugs with different mecha-
nisms of action to achieve glycemic targets over time [7]. 
Dipeptidyl peptidase 4 (DPP-4) inhibitors have become 
a useful class of oral hypoglycemic agents (OHA) for the 
treatment of T2DM since 2006. DPP-4 is a transmem-
brane glycoprotein located on the surface of most cell 
types, and its multiple effects may be associated with 
immune regulation, cell apoptosis, and signal transduc-
tion [8]. The clinically relevant action of DPP-4 is the 
degradation of endogenous glucagon-like peptide 1 
(GLP-1). Additionally, DPP-4 inhibitors enhance insulin 
secretion in a glucose-dependent manner [9].
Several clinical practice guidelines recommend a step-
wise treatment pathway for diabetes. Diet control and 
lifestyle intervention are considered the cornerstones for 
treatment of DM according to these guidelines. How-
ever, dietary and lifestyle changes are difficult to imple-
ment and maintain on a large scale. Given the progressive 
nature of T2DM, long-term glycemic control is difficult 
to achieve with a single agent, thus often requiring the 
addition of further agents [10]. The American Diabetes 
Association/European Association for the Study of Dia-
betes position statement and the American Association 
of Clinical Endocrinologists/American College of Endo-
crinology algorithm suggest the use of DPP-4 inhibitors 
as a second option when metformin fails [11]. Addition 
of a DPP-4 enzyme inhibitor to metformin treatment 
is beneficial owing to the complementary mechanisms 
of action of both drugs [11–14]. Nonetheless, the role 
of those new drugs in the treatment of T2DM is still 
debated [15]. A few clinical studies have reported the 
effect of DPP-4 inhibitors as an add-on therapy to insulin 
[16–18]. The efficacy in achieving glycemic control and 
weight-sparing effects of DPP-4 inhibitors have been 
stated in both systematic reviews and meta-analyses in 
comparison with placebo and other antidiabetic medi-
cations [19–21]. However, their safety and the efficacy 
when combined with traditional anti-hyperglycemic 
therapy remain inconclusive. Therefore, we conducted 
this study to evaluate the efficacy and safety of DPP-4 
inhibitor vildagliptin, sitagliptin, or linagliptin as add-on 
therapy for T2DM patients inadequately controlled with 
dual combination of insulin and metformin or acarbose.
Methods
Subjects
Patients were recruited from the Metabolic Diseases Hos-
pital of Tianjin Medical University between January 2013 
and January 2015. Enrolled male or female patients met 
the following criteria: diagnosis of T2DM; age >18 years; 
HbA1c levels >7.0 %; body mass index (BMI) between 22 
and 45 kg/m2 at visit 1 (week −4); current treatment with 
insulin at a stable dose of 20–80 U daily and a traditional 
OHA (metformin 750–1000  mg daily or acarbose 100–
300 mg daily) for at least 12 weeks before screening.
Patients who met the following criteria were excluded 
from the study: pregnant or lactating women; diagnosis 
of type 1 diabetes mellitus, diabetes secondary to pan-
creatic injury or other types of secondary diabetes; acute 
metabolic diabetic complications, such as ketoacidosis 
or hyperosmolar state (coma) within the 3 months prior 
to enrollment; myocardial infarction, unstable angina or 
coronary artery bypass surgery within 6  months prior 
to enrollment; congestive heart failure (NYHA III-IV 
grade); history of liver disease such as cirrhosis, hepatitis 
B, or hepatitis C (except carriers), or alanine transami-
nase (ALT), aspartate aminotransferase (AST) greater 
than two times the upper limit of normal (ULN) or total 
bilirubin greater than two times the ULN; history of kid-
ney disease or clinical diagnosis of renal insufficiency 
indicated by serum creatinine  ≥132  μmol/L (≥1.5  mg/
dL) in male patients, and ≥123 μmol/L (≥1.4 mg/dL) in 
female patients; thyroid-stimulating hormone beyond 
the normal range; and history of acute and chronic 
pancreatitis.
Written informed consent was obtained from each 
patient prior to enrollment. This study design was 
approved by the local ethics committee and review board 
and was in accordance with the Declaration of Helsinki.
Study design
This was a 12-week, randomized, open-label, parallel 
clinical study. The flow diagram of the study design 
is presented in Fig.  1. Patients with T2DM who met 
the inclusion criteria were screened for eligibility 
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at Visit 1 (week −4) and were randomized (1:1:1) 
at Visit 2 (week 0, baseline) to receive vildagliptin 
50  mg bid, sitagliptin 100  mg qd, or linagliptin 5  mg 
qd for 12  weeks. Patients were required to maintain 
their individual eating and exercise habits during the 
study, and follow all the study requirements as well. At 
and after the screening visit, baseline laboratory and 
clinical data were evaluated in every case. The DPP-4 
inhibitor was administered as an add-on therapy to 
the background OHA maintained throughout the 
study. The patients were followed up every 2 weeks in 
the outpatient department. Dose adjustments of insu-
lin or analogs were performed by the treating physi-
cians according to the level of the blood glucose at 
each visit.
Study assessments and endpoints
The primary study endpoint was change in HbA1c and 
the proportion of patients that reached the target HbA1c 
level (<7.0 %) [22] from baseline to week 12. Secondary 
efficacy assessments included changes in FPG, PPG, and 
the insulin dose from baseline to endpoint (week 12). 
Safety assessments included recording and monitoring of 
treatment-emergent adverse events (AEs); biochemistry 
and hematology laboratory test results; electrocardio-
gram findings and vital signs. Hypoglycemia was defined 
as symptoms suggestive of hypoglycemia with a self-
monitored plasma glucose measurement  <3.1  mmol/L. 
Severe hypoglycemia was defined as an episode requiring 
external assistance or hospitalization with or without a 
plasma glucose measurement <3.1 mmol/L.
Fig. 1 Flow diagram of the patient recruitment process
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Statistical analysis
All the measurement data were expressed as 
mean ± standard deviation. One-way analysis of variance 
was used to compare the differences in clinical charac-
teristics between the three groups at baseline and after 
treatment. Fisher’s least significant difference test was 
adopted for multiple comparisons. Chi square test was 
performed for analysis of differences in the frequency 
distributions. The data were analyzed by SPSS 18.0 for 
Windows (SPSS Inc., Chicago, IL, USA). P  <  0.05 was 
considered statistically significant.
Results
Patient Disposition and Baseline Characteristics
The disposition of patients from screening to study end-
point is depicted in Fig. 1. Of total 600 patients screened, 
535 were randomized to receive vildagliptin (n  =  178), 
sitagliptin (n  =  178), and linagliptin (n  =  179) respec-
tively. 166 of 178 (93.3  %) patients in the vildagliptin 
group, 165 of 178 (92.7  %) in the sitagliptin group, and 
164 of 179 (91.6 %) in the linagliptin group completed the 
study. Discontinuation in the three groups was mainly 
due to loss to follow-up, adverse events (mainly hypogly-
cemia), or other reasons.
The baseline characteristics of the randomized patients 
are presented in Table 1. The three groups were well bal-
anced at baseline in terms of gender, age, BMI, disease 
duration, insulin dose and background therapy (insu-
lin and OHA). All biochemistry indexes were matched 
between groups except for blood urea nitrogen (BUN).
Efficacy
At baseline HbA1c was 9.59  ±  1.84  % in the vilda-
gliptin group, 9.22  ±  1.60  % in the sitagliptin group, 
and 9.58  ±  1.80  % in the linagliptin group, no differ-
ences was found between the three groups (P =  0.097). 
After 12  weeks of treatment, it was reduced to 
8.16 ±  1.29  % (vildagliptin), 8.56 ±  1.96  % (linagliptin), 
and 8.26 ± 1.10 % (sitagliptin). Except that the vildaglip-
tin group had a lower HbA1c value than the linagliptin 
group (P  =  0.044), no significant differences in HbA1c 
were found between the groups (Fig. 2a).
The change in HbA1c from baseline was the most 
important end point of our study. As mentioned above 
all three groups had a decline in HbA1c but the vilda-
gliptin group had the greatest one (−1.33  ±  0.11  %) 
(P =  0.000). The changes in HbA1c were −0.84 ±  0.08 
and −0.81  ±  0.08  % in the sitagliptin and linagliptin 
groups, respectively (Fig. 2b).
66.27  % of patients in the vildagliptin group achieved 
target HbA1c level, whereas in sitagliptin group the pro-
portion was 52.73 % and in the linagliptin group 55.49 %. 
The vildagliptin group had the highest proportion that 
reached target HbA1c among the three groups (P < 0.05) 
(Fig. 2c).
Mean FPG values during the 12  weeks of treat-
ment are presented in Fig.  3a. The baseline values 
in the three groups were at the same level. At week 
6, they were 6.68  ±  1.03  mmol/L in the vildagliptin 
group, 7.22 ± 1.47 mmol/L in the sitagliptin group, and 
6.95  ±  1.27  mmol/L in the linagliptin group. All three 
groups revealed a decline in FPG when compared with 
their baseline levels, but it was more significant in the 
vildagliptin arm than in the other two groups (P = 0.001). 
At week 12, mean FPG levels were 7.31 ± 1.50 mmol/L in 
the vildagliptin group and 6.90 ± 1.55 mmol/L in the lin-
agliptin group, significantly lower when compared with 
the sitagliptin group (8.02 ± 4.48 mmol/L; P = 0.002).
The mean PPG values during the 12  weeks of the 
study are depicted in Fig.  3b. The values at baseline 
were 15.05  ±  4.02  mmol/L in the vildagliptin group, 
14.82  ±  3.58  mmol/L in the sitagliptin group, and 
15.21 ± 3.78 mmol/L in the linagliptin group. No differ-
ences were found between the three groups (P = 0.653). 
All three groups revealed a reduction in PPG after 
treatment, but to a slightly different degree. At week 6, 
the mean PPG was 9.09  ±  1.83  mmol/L (vildagliptin), 
9.16 ± 2.24 mmol/L (linagliptin) and 9.80 ± 2.23 mmol/L 
(sitagliptin). The value was significantly lower in the 
vildagliptin group and linagliptin group than in the sit-
agliptin group (P  =  0.004). At week 12, the value was 
9.03  ±  2.53  mmol/L (linagliptin), 9.80  ±  2.22  mmol/L 
(vildagliptin) and 10.58 ± 2.64 mmol/L (sitagliptin). The 
linagliptin group had the lowest mean PPG followed by 
the vildagliptin group. Although the value in the vilda-
gliptin group was not as low as in the linagliptin group, it 
was significantly lower (P = 0.000) than that in the sitag-
liptin group.
A decline in mean insulin dose was noticed in the 
three groups over the 12-week study period. At base-
line, the dose was 33.15  ±  12.89 U in the vildagliptin 
group, 36.02  ±  13.09 U in the sitagliptin group, and 
33.43  ±  15.76 U in the linagliptin group (P  =  0.121). 
At week 6 the dose was 23.92  ±  0.96 U (vildagliptin), 
24.89 ±  1.28 U (linagliptin) and 28.29 ±  1.06 U (sitag-
liptin). The vildagliptin group had the lowest insulin 
dose. The dose in the linagliptin group, though not as 
low as in the vildagliptin group, was lower than in the 
sitagliptin group (P =  0.014). At week 12 the dose was 
20.71  ±  12.36 U (vildagliptin), 27.34  ±  13.46 U (sitag-
liptin) and 24.81  ±  15.08 U (linagliptin). Comparison 
between groups showed that the mean insulin dose was 
much lower in the vildagliptin group than in the other 
two groups (P = 0.000) (Fig. 4a).
In the present study change in insulin dose was an 
important variable which demonstrated a downward 
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trend in the three groups. At week 6, the change was 
−9.17 ±  0.95 U in the vildagliptin group, −7.73 ±  0.86 
U in the sitagliptin group, and −8.85  ±  0.88 U in the 
linagliptin group. No differences were found between 
the three groups. At week 12, however, the change was 
−12.24 ±  1.11 U (vildagliptin), −12.81 ±  1.13 U (sitag-
liptin) and −8.63 ± 0.93 U (linagliptin). The change was 
more pronounced in the vildagliptin group and sitagliptin 
group than in the linagliptin group (P = 0.013) (Fig. 4b).
We measured the participants’ BMI, blood pressure, 
and lipid profile during the 12-week follow-up. There 
were no changes in BMI and blood pressure. The total 
cholesterol (TC) and triglycerides (TG) in the three 
groups showed a downtrend when compared with the 
baseline, but the differences were not significant. In addi-
tion no differences in TC and TG at week 6 or 12 were 
found between the groups (data not shown).
Safety
No severe AEs were reported in the three groups. All the 
AEs reported during the study were mild. The most com-
monly reported AEs were gastrointestinal AEs (14.46  % 
for vildagliptin, 11.52  % for sitagliptin, and 9.15  % for 
linagliptin). The other frequently reported AE was 
hypoglycemia (12.05 % for vildagliptin, 10.3 % for sitag-
liptin, and 7.29  % for linagliptin). There were very low 
incidences of renal and hepatic toxicity, infections, and 
chest discomfort. There was no significant difference 
between groups in terms of reported AEs (Table 2).
Discussion
The inability of monotherapy to maintain good glyce-
mic control in T2DM as a result of progressive dete-
rioration of β-cell function provides the rationale for the 
early use of combination therapy with different classes of 
drugs. For the same reason, insulin therapy is frequently 
required to achieve sufficient glycemic control. However, 
insulin therapy may lead to weight gain, increasing risk of 
hypoglycemia, edema, and some other side effects [23]. 
Considering all these benefits and harms, the chosen 
therapeutic regimen must be balanced to achieve glyce-
mic control and decrease the dose of insulin needed.
This 12-week, randomized, open-label, parallel study 
evaluated the efficacy and safety of vildagliptin, sitagliptin, 
or linagliptin in Chinese patients with T2DM inadequately 
controlled on dual combination of insulin and a traditional 
OHA. All the groups achieved a better glycemic control 
compared with baseline both at weeks 6 and 12. The FPG 
Table 1 Baseline characteristics of the participants
Values are expressed as mean ± SD or n (%). BUN in the linagliptin group was lower than the other two groups (P < 0.05)
ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, BUN blood urea nitrogen, SBP systolic blood pressure, Cr creatinine, DBP diastolic blood 
pressure, OHA oral hypoglycemic agent, TC total cholesterol, TG triglyceride
Variables Vildagliptin (n = 166) Sitagliptin (n = 165) Linagliptin (n = 164) For χ2 values P values
Male, n (%) 92 (55.4) 104 (63.0) 104 (63.4) 2.817 0.245
Age (years) 56.20 ± 10.37 56.04 ± 13.80 54.66 ± 10.85 0.851 0.428
BMI (kg/cm2) 26.49 ± 6.44 26.51 ± 4.29 26.82 ± 4.80 0.198 0.821
Disease duration (years) 7.78 ± 0.58 8.50 ± 0.62 7.51 ± 0.53 0.779 0.459
SBP (mmHg) 131.63 ± 16.41 130.92 ± 15.32 131.53 ± 18.71 0.085 0.918
DBP (mmHg) 79.85 ± 8.92 80.33 ± 7.93 81.38 ± 11.02 1.122 0.326
ALT (IU/L) 23.98 ± 13.83 23.87 ± 14.56 27.34 ± 16.70 2.397 0.092
AST (IU/L) 20.51 ± 9.36 22.75 ± 10.64 22.01 ± 10.98 1.898 0.151
BUN (mmol/L) 5.93 ± 1.79 6.32 ± 2.58 5.49 ± 1.35 5.639 0.004
Cr (umol/L) 66.08 ± 45.22 69.09 ± 23.88 64.08 ± 13.88 0.880 0.416
TG (mmol/L) 2.14 ± 2.01 2.29 ± 1.82 2.26 ± 1.72 0.286 0.751
TC (mmol/L) 5.16 ± 1.24 5.30 ± 1.36 5.09 ± 1.04 1.017 0.363
HbA1c (%) 9.59 ± 1.84 9.22 ± 1.60 9.58 ± 1.80 2.345 0.097
Insulin dose (U) 33.15 ± 1.00 36.02 ± 1.06 33.43 ± 1.23 2.121 0.121
Insulin therapy, n (%)
 Premixed human insulin 65 (39.15) 81 (49.00) 64 (39.02) 7.270 0.122
 Premixed insulin analogs 42 (25.30) 44 (26.67) 41 (25.00)
 Basal insulin 59 (35.54) 40 (25.32) 59 (35.98)
Background OHA, n (%)
 Metformin 80 (48.2) 93 (56.4) 90 (54.9) 2.519 0.284
 Acarbose 86 (51.8) 72 (43.6) 74 (45.1)
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values decreased in the three groups after treatment with 
vildagliptin, sitagliptin, or linagliptin but to a slightly differ-
ent degree. At week 12, vildagliptin and linagliptin induced 
a significantly greater decrease in FPG than sitagliptin did. 
Similarly, vildagliptin and linagliptin induced significantly 
greater decline in PPG when compared with sitagliptin. 
At week 12, patients treated with linagliptin revealed the 
most remarkable decrease in the PPG levels, followed by 
vildagliptin. The three DPP-4 inhibitors showed excel-
lent effect on glycemic control as add-on therapy in treat-
ing T2DM. Our results are in accordance with previous 
Fig. 2 a HbA1c during the 12‑week treatment with vidagliptin, 
sitagliptin, or linagliptin. There were no differences in HbA1c at 
baseline. Levels of HbA1c in the vildagliptin group were lower than in 
the linagliptin group at week 12 (P < 0.05). b HbA1c changes during 
the 12 weeks in the vildagliptin, sitagliptin, or linagliptin group. The 
change in HbA1c in the vildagliptin group was the greatest among 
the three groups (P < 0.05). c Proportion of patients. The proportion 
of patients achieving the target HbA1c levels in the vildagliptin group 
was the greatest among the three groups (P < 0.05)
Fig. 3 a Changes in FPG during the 12‑week treatment with vilda‑
gliptin, sitagliptin, or linagliptin. The FPG levels in the three groups 
showed no difference at week 0. The FPG in the vildagliptin group 
was the lowest at week 6 (*P < 0.05). The FPG levels in the vildagliptin 
and linagliptin groups were lower than in the sitagliptin group at 
week 12 (*P < 0.05). b Changes in PPG during the 12 weeks in the 
vildagliptin, sitagliptin, or linagliptin group. The PPG levels were not 
significantly different between the groups. The PPG levels in the 
vildagliptin and linagliptin groups were lower than in the sitagliptin 
group at week 6 (*P < 0.05). The PPG in the linagliptin group was the 
lowest one, and the PPG in the vildagliptin group was lower than in 
the sitagliptin group at week 12 (*P < 0.05)
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reports [16, 18, 24]. The present study showed vildagliptin, 
sitagliptin, and linagliptin help decrease FPG and PPG as 
add-on therapy to the background insulin treatment.
Our primary study end point was the change in 
HbA1c during the follow-up. At week 12 all three groups 
achieved significant change in HbA1c but the change in 
the vildagliptin arm was statistically greater than in the 
other two groups. Several previous reports demonstrated 
that vildagliptin, sitagliptin, and linagliptin are efficacious 
in decreasing HbA1c and enabled patients to reach glyce-
mic control targets both as monotherapy and combina-
tion therapy [18, 19, 25–27]. Our study results are similar 
to those of previous studies in these regards. Moreover, 
as far as we know, this study is the first to compare vilda-
gliptin, sitagliptin, and linagliptin as add-on therapy for 
T2DM patients with background insulin treatment. And 
what is more, our results indicate that vildagliptin is more 
effective in decreasing HbA1c.
It is generally acknowledged that high insulin doses 
might cause various unwanted effects during the treat-
ment of T2DM. The present study extended the DPP-4 
inhibitor treatment period to 12  weeks so that we were 
able to see the gradual decrease in blood glucose and 
the consequent decline in HbA1c. The gradual decline 
of blood glucose substantially decreased insulin require-
ment and resulted in considerable insulin dose reduction. 
Insulin doses in the vildagliptin group at weeks 6 and 12 
were the lowest among the three groups. Additionally, the 
changes in insulin doses in the vildagliptin and sitagliptin 
groups were much more pronounced than in the linaglip-
tin group.
The classical mechanism of the DPP-4 inhibitors to 
achieve glycemic control is based on the notion that these 
drugs increase the active levels of incretin hormones, 
GLP-1 and glucose-dependent insulinotropic polypep-
tide (GIP), and thereby improving pancreatic A- and B 
cell sensitivity to glucose [28]. A growing body of evi-
dence both from clinical and preclinical findings supports 
the notion that DPP-4 inhibitors can ameliorate insulin 
resistance through several pathways [29, 30]. Thus, these 
findings might be potential explanations as to why add-
ing DPP-4 inhibitors to background insulin therapy could 
considerably decrease the required dosage of insulin.
The safety of DPP-4 inhibitors as add-on therapy to 
background insulin treatment in T2DM patients was one 
Fig. 4 a Insulin doses during the 12‑week treatment with vildaglip‑
tin, sitagliptin, or linagliptin. The insulin doses at week 0 were not 
significantly different. The insulin dose in the vildagliptin group was 
lower than in the sitagliptin group at week 6. The insulin dose in the 
linagliptin group was lower than in the sitagliptin group at week 6. 
The mean insulin dose in the vildagliptin group was much lower than 
in the other two groups at week 12 (P < 0.05). b Insulin changes dur‑
ing the 12‑week treatment with vildagliptin, sitagliptin, or linagliptin. 
There were no significant differences between the three groups at 
week 6. The insulin changes in the vildagliptin and sitagliptin groups 
were much more pronounced than in the linagliptin group (P < 0.05). 
FPG fasting plasma glucose, HbA1c glycosylated hemoglobin, PPG 
postprandial plasma glucose
Table 2 Adverse events during the 12 weeks
Variables, n (%) Vildagliptin (n = 166) Sitagliptin (n = 165) Linagliptin (n = 164) χ2 values P values
Hypoglycemia 20 (12.05) 17 (10.30) 13 (7.29) 1.554 0.460
Gastrointestinal adverse events 24 (14.46) 19 (11.52) 15 (9.15) 2.260 0.323
Renal and hepatic toxicity 6 (3.61) 5 (3.30) 2 (1.22) 2.008 0.366
Infections 10 (6.02) 8 (4.85) 12 (7.32) 0.881 0.644
Chest discomfort 8 (4.82) 11 (6.70) 11 (6.71) 0.676 0.713
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of the relevant aspects being evaluated in the present 
study. The main AEs included gastrointestinal AEs, hypo-
glycemia, renal and hepatic toxicity, infections (including 
upper respiratory and urinary tract infections and naso-
pharyngitis), and chest discomfort. During this study, no 
pancreatitis was reported. The risk of hypoglycemia was 
similar in the three groups. As previously reported in 
meta-analyses, the rate of hypoglycemia was not higher 
in T2DM patients treated with the DPP-4 inhibitors, even 
in patients already undergoing treatment with insulin or 
a sulfonylurea [31, 32]. In accordance with our results, a 
meta-analysis reported that there was no increased inci-
dence of gastrointestinal disorders in patients treated 
with DPP-4 inhibitors [33]. Moreover, the rates of other 
AEs in the present study were low and were not signifi-
cantly different between the three groups.
The present study had certain limitations that need to 
be recognized. The study was performed in a relatively 
small number of patients at a single institution. Further 
studies are required to evaluate the long-term effects 
of DPP-4 inhibitors with or without insulin on glyce-
mic control and insulin secretion in a larger number 
of patients. We did not recruit a group without DPP-4 
inhibitors as controls, which is also a limitation to this 
study. Additionally, close pharmacovigilance monitoring 
plans are necessary to address the uncertainty regard-
ing AEs of DPP-4 inhibitors, while their potential impact 
on cardiovascular outcomes will be clarified in the near 
future after the completion of more relevant long-term 
studies.
Conclusions
Vildagliptin, sitagliptin, or linagliptin appear to be effec-
tive and safe as add-on treatment for T2DM patients 
inadequately controlled on dual combination of insulin 
and another OHA. This is the first study to evaluate the 
efficacy and safety of this treatment regimen in Chinese 
T2DM patients. The three DPP-4 inhibitors had similar 
efficacy in achieving glycemic control, but vildagliptin 
was much more efficacious in decreasing insulin require-
ment and achieving target HbA1c level. Therefore, we 
consider that vildagliptin or any of the other tested 
DPP-4 inhibitors could be added to combination therapy 
to reach the glycemic control in inadequately controlled 
patients.
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